Answers are grounded in this paper and cite their sources.
CONTEXT: Intravenous zoledronate prevents bone loss and reduces fracture risk in older adults but the optimal dosing strategy required to achieve each outcome is not known. OBJECTIVE: To assess the effect of very infrequent zoledronate therapy on bone mineral density (BMD) and markers of bone turnover. DESIGN AND PARTICIPANTS: An average of 5.5 years after randomization to either a single dose of 5 mg of zoledronateor placebo, 33 of the original cohort of 50 older women with osteopenia entered a 5-year open-label extension study. SETTING: Academic research center. INTERVENTION: A 5-mg dose of intravenous zoledronate was administered to all participants. MAIN OUTCOME MEASURES: BMD and bone turnover were measured annually, generating data over almost 11 years in women who received 5 mg of zoledronate at 0 and 5.5 years (ZZ, n = 16), or placebo at baseline and 5 mg of zoledronate at 5.5 years (PZ, n = 17). RESULTS: After redosing, BMD in ZZ remained stable, while BMD in PZ increased. At 11 years, changes from baseline BMD in ZZ and PZ were 3.8% (95% confidence interval (CI) 1.1,6.5) and 2.9% (0.3,5.5) at the lumbar spine (P = .61), 0.9% (-1.7,3.5) and -2.8% (-5.3,-0.3) at the total hip (P = .006), and 0.4% (-0.8,1.6) and -0.4% (-1.3,0.5) at the total body (P = .14). Bone turnover markers were similar in the PZ and ZZ groups throughout the 5 years after redosing. CONCLUSIONS: These results suggest that zoledronate 5 mg administered at a 5.5-year interval prevents bone loss over almost 11 years. Clinical trials to investigate whether very infrequent treatment with zoledronate reduces fracture risk are justified.
No takes yet. Share an insight, caveat, or question.
Grey et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: